Zalutumumab
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Human |
Target | Epidermal growth factor receptor |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C6512H10074N1734O2032S46 |
Molar mass | 146643.09 g·mol−1 |
(what is this?) (verify) |
Zalutumumab (proposed trade name HuMax-EGFR) is a fully human IgG1
Mechanism of action
Zalutumumab works through inhibition of the EGFR signal. The EGFR is a
Mechanism of EGFR
EGFR is over-expressed by many tumor cells. Upon binding by a ligand, such as the
Mechanism of zalutumumab
In order to combat SCCHN, zalutumumab was designed to inhibit the EGFR signaling. Specifically, it binds to the EGFR Domain III on the cell surface. This locks the receptor in an inactive conformation, making the drug an
This is not the only way in which zalutumumab works. It also is responsible for some antitumor affects through
Developmental status
2009: Zalutumumab treatment was approved for
2010:A phase III study (of zalutumumab as an addition to 'best supportive care' in patients after failed standard platinum-based
2014:A study of zalutumumab as addition to chemoradiation for SCCHN showed no benefit,[5] and 94% developed a skin rash (11% severe enough to discontinue).
2015:Genmab not proceeding with zalutumumab.[6]
References
- ^ What is Cancer, MedicineNet.com
- ^ PMID 18427122.
- ^ "Science and Research". Genmmab A/S. 2009.
- ^ http://www.genengnews.com/news/bnitem.aspx?name=77261239 March 2010
- ^ "OncoBriefs: Zalutumumab Misses Mark in H&N Cancer". medpagetoday.com. 22 February 2014.
- ^ Design, inNottingham Web. "Welcome to UKMi National Medicines Information". www.ukmi.nhs.uk. Archived from the original on 2012-05-26. Retrieved 2015-10-31.